Bronchoscope Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Bronchoscope Market Trends and Insights

Growing Burden of Respiratory Diseases & Lung Cancer

GLOBOCAN 2022 logged 2.48 million new lung-cancer cases worldwide and projects 4.62 million by 2050, with Asia responsible for 63% of the load. The 2024 U.S. screening-age reduction to 50 years added 6.4 million eligible adults, stretching interventional capacity and reinforcing robotic bronchoscopy adoption. Chronic obstructive pulmonary disease affects more than 390 million people, underpinning baseline diagnostic demand. Rising case volumes draw bronchoscopy closer to primary care, rewarding portable, single-use devices that avoid capital outlays. China’s 28% jump in lung-cancer diagnoses from 2019-2024 highlights a geographic imbalance that tele-mentored bronchoscopy may help address.

Rapid Adoption of AI-Guided Navigation Bronchoscopy

Johnson & Johnson’s MONARCH QUEST, cleared in March 2025, automates path planning and trims catheter repositioning by 35-40%. Intuitive Surgical’s Ion upgrade gained clearance in October 2025 and now tops 900 global installs, using shape-sensing fiber optics to lift diagnostic yield to roughly 82%. Meta-analysis data place robotic yield 8-11 percentage points above traditional electromagnetic navigation. Noah Medical’s single-use Galaxy system extends these gains to ambulatory settings by embedding real-time tomosynthesis imaging. The shorter 40-60-case proficiency curve alleviates workforce bottlenecks, a critical lever where trained specialists are scarce.

Reimbursement Expansion for Single-Use Bronchoscopes

HCPCS C1601, active January 2024 through December 2026, delivers separate payment for disposable scopes on top of procedure reimbursement, neutralizing their higher per-case price in outpatient sites^{[1]Centers for Medicare & Medicaid Services, “HCPCS C1601: Single-Use Pulmonary Bronchoscope,” cms.gov} . UnitedHealthcare and Anthem adopted parallel coverage in 2024, citing reduced cross-contamination risk. ASCs, numbering 6,308 Medicare-certified centers in 2025, can now offer bronchoscopy without USD 40,000–60,000 capital spend per reusable scope. Manufacturers face a 2026 deadline to cement clinical evidence before pass-through expiration.

Shift Toward Office-Based/ASC Bronchoscopy

Eighty-two percent of U.S. hospitals owned or partnered with an ASC by 2024, anticipating migration of low-acuity procedures. Diagnostic bronchoscopy receives 35-45% lower Medicare payment in ASCs than hospital outpatient departments, creating a payer-driven push. Single-use scopes bypass sterilization, letting freestanding centers schedule same-day cases. Teleflex’s portable platform targets physician-office labs where procedure volumes are modest and capital budgets thin. Hospitals risk losing profitable diagnostics that subsidize complex therapeutics, challenging fellowship economics.

High Overhead Cost of Bronchoscopy Procedure

A 2024 CHEST analysis placed U.S. outpatient bronchoscopy at USD 2,800–3,500 per case, dropping to USD 1,800–2,200 in ASCs yet still beyond reach in markets where annual per-capita health spend is under USD 500. India’s 48% out-of-pocket share limits access to urban insured populations. CMS trimmed payment by 2.8% in the 2025 fee schedule, intensifying throughput pressure. Robotic platforms partly offset cost by elevating first-pass success, but anesthesia and monitoring remain fixed expenses.

Shortage of Trained Interventional Pulmonologists

Fewer than 1,500 board-certified specialists practice in the United States, and fellowship programs add only 80-90 graduates per year. China counts roughly 200-250 trained physicians for 1.4 billion people. Robotic systems cut the learning curve roughly in half, while remote proctoring on the Ion platform allows urban experts to supervise rural cases in real time^{[3]Intuitive Surgical, “Ion Navigation Software Clearance,” intuitive.com}. Single-use scopes with simpler controls enable supervised procedures by nurse practitioners where regulations permit.

Segment Analysis

By Product Type: Flexible Scopes Dominate Innovation

Flexible bronchoscopes owned 62.55% of bronchoscope market share in 2025 and are projected to expand at 10.25% CAGR to 2031, buoyed by robotic platforms that reach peripheral nodules previously inaccessible to manual scopes^{[2]Johnson & Johnson, “MONARCH QUEST FDA Clearance,” jnj.com}. Rigid scopes stay confined to central airway work in operating rooms and therefore grow slowly. Accessory disposables, ranging from biopsy forceps to cryoprobes, create a recurring revenue layer that scales with every additional procedure.

Robotic navigation raises diagnostic accuracy from about 70% with standard flexible scopes to 80-84%, pivoting clinical preference toward the new generation of intelligent instruments. Disposable accessories align with infection-control policies and avoid reprocessing downtime. Medtronic’s cryobiopsy probes, introduced in 2024, are expanding tissue-sampling indications, further lifting procedure complexity and volume.

Note: Segment shares of all individual segments available upon report purchase

By Usage: Single-Use Gains Despite Reusable Dominance

Reusable devices represented 65.53% of the bronchoscope market size in 2025 because hospitals still rely on installed capital fleets. Yet single-use scopes are accelerating at 15.85% CAGR, thanks to pass-through reimbursement that offsets their higher variable cost. Ambu and Boston Scientific command early traction in ASCs that lack centralized sterilization.

A reusable scope amortized across 400-500 uses averages USD 150-250 per case; contamination incidents and labor costs tilt the equation as FDA alerts increase board scrutiny. Single-use options deliver 1080p imaging in models such as Ambu’s aScope 5, removing historic performance gaps. When pass-through payments sunset in 2026, device makers must prove long-term economic value to sustain adoption.

By Application: ICU Airway Management Surges

Oncology sustained 36.63% of bronchoscope market size in 2025, but ICU airway management is rushing forward at 12.87% CAGR on the back of ventilator-associated pneumonia protocols. Guidelines now endorse bronchoscopy when imaging is inconclusive, making bedside access crucial.

Point-of-care systems such as Ambu’s aView let intensivists avoid moving unstable patients, limiting cross-infection. Diagnostic yield for opportunistic infections in immunocompromised patients surpasses 80% compared with roughly 55% for non-invasive tests. Oncology growth moderates due to rising prior-authorization hurdles, but early-stage detection keeps overall procedure numbers firm.

Note: Segment shares of all individual segments available upon report purchase

By End User: ASCs Gain as Hospitals Dominate

Hospitals retained 73.33% of end-user demand in 2025 given their dominance in complex therapeutic work and robotic installations. Ambulatory surgical centers, however, are on an 11.7% CAGR trajectory, fueled by payer directives and single-use economics that bypass sterilization infrastructure.

ASCs focus on diagnostic and simple therapeutic cases with <2% complication rates, while hospitals guard advanced interventions such as airway stenting. Office-based labs remain nascent but are growing where nurse practitioners can conduct supervised procedures. The decentralization trend threatens hospital revenue streams that subsidize fellowship training and capital amortization.

Geography Analysis

North America captured 42.13% of bronchoscope market share in 2025 on the back of 180–220 procedures per 100,000 population and early robotic uptake. The 2024 screening-age drop expanded the eligible pool by 6.4 million, yet trained-specialist shortages lengthened waitlists in many states. HCPCS C1601 accelerates single-use adoption across 6,308 ASCs, while Canada’s capped reimbursement and 4-8-week waits are spawning private clinics. Mexican demand divides between urban private hospitals and under-equipped public centers.

Asia-Pacific outpaces all regions at 9.51% CAGR through 2031. China’s state screening pushes, India’s respiratory-care expansion, and South Korea’s 2024 coverage of robotic bronchoscopy drive volume. Japan’s 28% senior population sustains COPD-related demand; however, 2024 reimbursement cuts encourage disposable-scope adoption to save labor costs. Australia’s 2024 clearance of Ambu’s aScope 5 extends services to remote clinics lacking sterilization.

Europe holds roughly one-quarter of global revenue and sees heterogeneous policy environments. Germany’s DRG incentives promote robotics for efficiency; Charité reported a 22% volume spike after installing Ion in 2024. NHS England pilots single-use scopes in community centers to cut 12-week waits. France added outpatient reimbursement in 2024 after a contamination scare. Fiscal limits in Italy and Spain postpone capital upgrades. Middle East programs in the UAE and Saudi Arabia broaden screening, whereas Latin American growth hinges on Brazilian and Argentine private sectors amid public-sector shortfalls.